Compare Amgen, Inc. (AMGN) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Honeywell International Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Honeywell International Inc trades at $226.1 (market cap $71.74B). The key difference: Amgen, Inc. is far larger — about 2.7× Honeywell International Inc's market cap, and Honeywell International Inc pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| AMGN | HON | |
|---|---|---|
Market Cap | $196.12B | $71.74B |
Sector | Health | Industrials |
52-Week High | $388.16 | $248.04 |
52-Week Low | $271.18 | $188.14 |
Enterprise Value | $241.41B | $96.08B |
Dividend Yield | 2.77% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Honeywell International (HON) trades at $226.42, up 1.34% with neutral technical signals. The company maintains strong profitability with 10.89% net margin and 26.41% ROE, though revenue declined slightly to $37.44B in 2025. Recent corporate actions include a 2:1 reverse stock split and dividend payment, while analyst consensus remains bullish with a $402.40 price target. Technical indicators show mixed signals with RSI neutral and ADX suggesting bullish momentum.
HON presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include declining profit margins and increased debt levels. The stock's current valuation at 18.08 P/E appears reasonable given growth prospects in automation and defense sectors, but investors should monitor execution of post-spinoff strategy and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
